Predicting outcome in acute myocardial infarction: an analysis investigating 175 circulating biomarkers.
暂无分享,去创建一个
B. Lindahl | G. Marko‐Varga | M. Rezeli | T. Jernberg | D. Erlinge | J. Spaak | T. Baron | L. Lindhagen | K. Eggers | M. Hjort
[1] D. Sobral-Filho,et al. Carbohydrate antigen 125 predicts pulmonary congestion in patients with ST-segment elevation myocardial infarction , 2019, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[2] David Schumacher,et al. Cardiac FGF23: a new player in myocardial infarction , 2019, Discoveries.
[3] M. Orho-Melander,et al. sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a Marker of Plaque Cell Apoptosis and Cardiovascular Events. , 2019, Stroke.
[4] Jeroen J. Bax,et al. Fourth universal definition of myocardial infarction (2018). , 2018, European heart journal.
[5] M. Abbasnezhad,et al. Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients , 2018, Journal of cardiovascular and thoracic research.
[6] M. Landray,et al. Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. , 2018, Journal of the American Society of Nephrology : JASN.
[7] E. Ingelsson,et al. Circulating proteins as predictors of incident heart failure in the elderly , 2018, European journal of heart failure.
[8] P. Almgren,et al. Elevated Markers of Death Receptor-Activated Apoptosis are Associated with Increased Risk for Development of Diabetes and Cardiovascular Disease , 2017, EBioMedicine.
[9] B. Lindahl,et al. Quantitation of 87 Proteins by nLC-MRM/MS in Human Plasma: Workflow for Large-Scale Analysis of Biobank Samples. , 2017, Journal of proteome research.
[10] A. Siegbahn,et al. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction , 2017, European journal of preventive cardiology.
[11] L. Wallentin,et al. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. , 2017, Clinical chemistry.
[12] A. Mayr,et al. Fibroblast growth factor 23 as novel biomarker for early risk stratification after ST-elevation myocardial infarction , 2016, Heart.
[13] M. Melamed,et al. FGF-23 and cardiovascular disease: review of literature , 2016, Current opinion in endocrinology, diabetes, and obesity.
[14] Hongchuan Jin,et al. Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis , 2016, BMC Cardiovascular Disorders.
[15] M. Sabatine,et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction , 2016, Journal of the American Heart Association.
[16] B. Fabris,et al. Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease , 2016, BioMed research international.
[17] The Uniprot Consortium,et al. UniProt: a hub for protein information , 2014, Nucleic Acids Res..
[18] P. Bottoni,et al. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. , 2015, Advances in experimental medicine and biology.
[19] G. Schuler,et al. Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial , 2014, Critical Care.
[20] P. Faggiano,et al. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies , 2014, Journal of cardiovascular medicine.
[21] M. Sabatine,et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). , 2014, Journal of the American College of Cardiology.
[22] J. Stenvang,et al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.
[23] A. Curnis,et al. Carbohydrate Antigen 125: A New Biomarker in Heart Failure , 2013, Cardiology in review.
[24] Martin Lundberg,et al. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood , 2011, Nucleic acids research.
[25] C. Heeschen,et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome , 2010, Heart.
[26] M. Sabatine,et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. , 2011, European heart journal.
[27] Michael Schocke,et al. Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. , 2011, International journal of cardiology.
[28] L. Schurgers,et al. The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.
[29] L. Wallentin,et al. Abstract 1428: Statin Use After Myocardial Iinfarction Improves Survival in Nearly All With Renal Dysfunction: Data From the Swedish Web-system for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) , 2009 .
[30] M. Bennett,et al. Death Receptors and Their Ligands in Atherosclerosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[31] D. Barnett,et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. , 2000, European heart journal.